Factors That Influence the Decision to Staff a Medical Information Booth at a Medical Meeting Meredith AbrahamErica HeverinEmily Hajjar Medical Information 30 December 2010 Pages: 351 - 358
How a Data-Driven Quality Management System Can Manage Compliance Risk in Clinical Trials Sina DjaliStef JanssensJan Van Parijs Medical Information 30 December 2010 Pages: 359 - 373
Assessment of a Simplified Format of Written Patient Prescription Drug Information Julie I. PapayDeborah FritzSandy Debussey Medical Information 30 December 2010 Pages: 375 - 391
Detection of Adverse Drug Reaction Signals in the Thai FDA Database: Comparison between Reporting Odds Ratio and Bayesian Confidence Propagation Neural Network Methods Waranee BunchuailuaIlene H. ZuckermanJaranit Kaewkungwal Pharmacovigilance 30 December 2010 Pages: 393 - 403
SCORE Study Report 8: Closed Tests for All Pairwise Comparisons of Means Neal OdenPaul C. Van VeldhuisenMichael S. Ip Biostatistics 30 December 2010 Pages: 405 - 420
Design Archetypes for Phase 2 Clinical Trials in Central Nervous System Disorders Craig H. MallinckrodtMichael J. DetkeGeert Molenberghs Biostatistics 30 December 2010 Pages: 421 - 430
Considerations for Using Positive Controls in Phase 2 Clinical Trials of Central Nervous System Disorders Craig H. MallinckrodtMichael J. DetkeGeert Molenberghs Biostatistics 30 December 2010 Pages: 431 - 441
Considerations for Comparing a Test Drug with Standard of Care in Phase 2 Clinical Trials of Central Nervous System Disorders Craig H. MallinckrodtMichael J. DetkeGeert Molenberghs Biostatistics 30 December 2010 Pages: 443 - 452
An Application of a Bayesian Approach in Diagnostic Testing Problems in the Absence of a Gold Standard Faiz Ahmad Biostatistics 30 December 2010 Pages: 453 - 462
Standard Operating Procedures (SOPs): How to Write Them to Be Effective Tools Janet GoughMichael Hamrell Regulatory Affairs 30 December 2010 Pages: 463 - 468
Overview of the FDA Amendments Act of 2007: Its Effect on the Drug Development Landscape Raj KishoreEdward Tabor Regulatory Affairs 30 December 2010 Pages: 469 - 475
PhRMA BioResearch Monitoring Committee Perspective on Acceptable Approaches for Clinical Trial Monitoring Roland W. Usher Regulatory Affairs 30 December 2010 Pages: 477 - 483
Summary of DIA Workshop: Comparability Challenges: Regulatory and Scientific Issues in the Assessment of Biopharmaceuticals Richard M. LewisMary Ellen Cosenza Regulatory Affairs 30 December 2010 Pages: 485 - 504
2010 Annual Meeting Student Poster Abstracts Springer 2010 Annual Meeting 30 December 2010 Pages: 505 - 511
